EUVIMEDEUVIMED entdecken
Open Access

Opportunities for Improving Glaucoma Clinical Trials via Deep Learning-Based Identification of Patients with Low Visual Field Variability

Ruolin Wang, Chris Bradley, Patrick Herbert, Kaihua Hou, Gregory D Hager, Katharina Breininger, Mathias Unberath, Pradeep Ramulu, Jithin Yohannan

Ophthalmology Glaucoma · 2024

DOI: 10.1016/j.ogla.2024.01.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmology Glaucoma, 2024. Verfasst von Ruolin Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Malone Center for Engineering in Healthcare, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department Artificial Intelligence in …. Hauptthemen laut MEDLINE: Deep Learning, Visual Fields, Intraocular Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, BrightFocus Foundation, Arvo Foundation for Eye Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Develop and evaluate the performance of a deep learning model (DLM) that forecasts eyes with low future visual field (VF) variability, and study the impact of using this DLM on sample size requirements for neuroprotective trials. DESIGN: Retrospective cohort and simulation study. METHODS: We included 1 eye per patient with baseline reliable VFs, OCT, clinical measures (demographics, intraocular pressure, and visual acuity), and 5 subsequent reliable VFs to forecast VF variability using DLMs and perform sample size estimates. We estimated sample size for 3 groups of eyes: all eyes (AE), low variability eyes (LVE: the subset of AE with a standard deviation of mean deviation [MD] slope residuals in the bottom 25th percentile), and DLM-predicted low variability eyes (DLPE: the subset of AE predicted to be low variability by the DLM). Deep learning models using only baseline VF/OCT/clinical data as input (DLM1), or also using a second VF (DLM2) were constructed to predict low VF variability (DLPE1 and DLPE2, respectively). Data were split 60/10/30 into train/val/test. Clinical trial simulations were performed only on the test set. We estimated the sample size necessary to detect treatment effects of 20% to 50% in MD slope with 80% power. Power was defined as the percentage of simulated clinical trials where the MD slope was significantly worse from the control. Clinical trials were simulated with visits every 3 months with a total of 10 visits. RESULTS: A total of 2817 eyes were included in the analysis. Deep learning models 1 and 2 achieved an area under the receiver operating characteristic curve of 0.73 (95% confidence interval [CI]: 0.68, 0.76) and 0.82 (95% CI: 0.78, 0.85) in forecasting low VF variability. When compared with including AE, using DLPE1 and DLPE2 reduced sample size to achieve 80% power by 30% and 38% for 30% treatment effect, and 31% and 38% for 50% treatment effect. CONCLUSIONS: Deep learning models can forecast eyes with low VF variability using data from a single baseline clinical visit. This can reduce sample size requirements, and potentially reduce the burden of future glaucoma clinical trials. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deep LearningVisual FieldsIntraocular PressureHumansRetrospective StudiesFemaleMaleClinical Trials as TopicGlaucomaVisual AcuityAgedVisual Field TestsMiddle AgedTomography, Optical Coherence

Stichwörter der Autor:innen

Clinical trialsDeep learningGlaucomaOCTSample size

Autor:innen und Institutionen

  • Malone Center for Engineering in Healthcare, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department Artificial Intelligence in Biomedical Engineering, Friedrich-Alexander-Universität Erlangen-Nürnb…
  • Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Malone Center for Engineering in Healthcare, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Department Artificial Intelligence in Biomedical Engineering, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Malone Center for Engineering in Healthcare, Johns Hopkins University School of Medicine, Baltimore, Maryland; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address:…

Förderung

  • NEI NIH HHS
  • BrightFocus Foundation
  • Arvo Foundation for Eye Research
  • Research to Prevent Blindness
  • National Eye Institute
  • National Institutes of Health

Zitieren

APA

Wang, R., Bradley, C., Herbert, P., Hou, K., Hager, G. D., Breininger, K., Unberath, M., Ramulu, P., & Yohannan, J. (2024). Opportunities for Improving Glaucoma Clinical Trials via Deep Learning-Based Identification of Patients with Low Visual Field Variability. Ophthalmology Glaucoma. https://doi.org/10.1016/j.ogla.2024.01.005

Vancouver

Wang R, Bradley C, Herbert P, Hou K, Hager GD, Breininger K, et al. Opportunities for Improving Glaucoma Clinical Trials via Deep Learning-Based Identification of Patients with Low Visual Field Variability. Ophthalmology Glaucoma. 2024. doi:10.1016/j.ogla.2024.01.005

BibTeX
@article{Wang2024,
  author = {Wang, Ruolin and Bradley, Chris and Herbert, Patrick and Hou, Kaihua and Hager, Gregory D and Breininger, Katharina and Unberath, Mathias and Ramulu, Pradeep and Yohannan, Jithin},
  title = {Opportunities for Improving Glaucoma Clinical Trials via Deep Learning-Based Identification of Patients with Low Visual Field Variability},
  journal = {Ophthalmology Glaucoma},
  year = {2024},
  doi = {10.1016/j.ogla.2024.01.005}
}
Kostenlos starten →